Comparison 5. Three infusions of natalizumab (300 mg) and two infusions of infliximab versus placebo and two infusions of infliximab.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Failure to induce clinical remission at week 10 | 1 | 79 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.90 [0.65, 1.24] |
2 Failure to induce remission at week 10 in patients with elevated CRP at baseline (posthoc subgroup analysis) | 1 | 35 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.73 [0.55, 0.97] |
3 Adverse events | 1 | 79 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.93 [0.85, 1.03] |
4 Withdrawal due to adverse events | 1 | 79 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.18 [0.01, 4.18] |
5 Serious adverse events | 1 | 79 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.52 [0.03, 7.98] |